From: Nitric oxide in occurrence, progress and therapy of lung Cancer: a systemic review and meta-analysis
Year | Author | Country | Age (Mean ± SD) | Sex (M/F) | Smoking status | Histology | Stage | Treatment | Follow up period | Blood NO (μmol/L) | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Before therapy | After therapy | ||||||||||||
Mean ± SD | n | Mean ± SD | n | ||||||||||
1997 | Zhang | China | 58.4a | 13/7 | NA | SCC, ADC, LCC, SCLC | advanced | chemo-therapy | 1 week | 51.2 ± 16.9 | 10 | 79.8 ± 21.3 | 10 |
1998 | Yu | China | 64.2a | 28/18 | NA | SCC, ADC | early + advanced | surgery | NA | 7.51 ± 1.40 | 26 | 6.68 ± 1.19 | 26 |
chemo-therapy | NA | 6.58 ± 1.30 | 15 | 5.43 ± 1.43 | 15 | ||||||||
1999 | Yu | China | 49 士 3.8 | 14/4 | NA | SCC, ADC | early + advanced | chemo-therapy /surgery | NA | 9.91 ± 1.03 | 18 | 8.48 ± 1.06 | 18 |
2002 | Li | China | 64.3b (37–75) | 53/31 | NA | SCC, ADC | early + advanced | chemo-therapy | NA | 64.6 ± 29.5 | 84 | 88.9 ± 39.4 | 84 |
2002 | Wang | China | 65.4a | 35/13 | NA | SCC, ADC, LCC | early + advanced | surgery | NA | 7.124 ± 1.631 | 26 | 6.094 ± 0.917 | 26 |
2003 | Liu | China | 61.4 ± 11.3 | 30/6 | NA | SCC, ADC | NA | surgery | 10 days | 8.72 ± 1.96 | 20 | 6.83 ± 1.75 | 20 |
2003 | Zhao | China | 51.8a | 28/12 | NA | NA | early | surgery | 1 month | 60.4 ± 27.2 | 40 | 37.8 ± 15.1 | 40 |
2005 | Yin | China | 57.04 ± 11.87 | 33/8 | NA | SCC, ADC, SCLC | early + advanced | chemo-therapy | 2 weeks | 38.03 ± 36.59 | 40 | 29.33 ± 20.97 | 40 |
2005 | Chen | China | NA | NA | NA | NA | early | surgery | 3 months | 30.4 ± 12.9 | 31 | 62.2 ± 15.1 | 30 |
2006 | Li | China | 57.8a | 47/15 | NA | SCC, ADC | early + advanced | surgery | 21 days | 86.7 ± 24.1 | 19 | 84.7 ± 18.4 | 19 |
chemo-therapy | 21 days | 89.4 ± 22.1 | 27 | 55.7 ± 16.7 | 27 | ||||||||
2006 | Colakogullari | Turkey | 58.5 ± 10.6 | 25/6 | NA | NSCLC, SCLC | advanced | chemo-therapy | 2 days | 93.0 ± 48.0 | 31 | 106.0 ± 49.0 | 16 |
2010 | Srivastava | India | 55b (30–88) | 155 / 48 | NA | mainly SCC, ADC, LCC | advanced | chemo-therapy | 88 weeks | 25.76 ± 4.54 | 203 | 32.81 ± 4.27 | 155 |
2015 | Xu | China | 36–80c | 24/12 | NA | SCC, ADC, LCC, SCLC | NA | chemo-therapy | NA | 30.1 ± 11.7 | 36 | 62.0 ± 14.7 | 36 |
2017 | Muto | Japan | 65.3 ± 6.3 | 6/9 | NA | ADC | advanced | chemo-therapy | > 30 months | 62.7 ± 40.0 | 15 | 37.6 ± 27.5 | 15 |
2019 | Feng | China | 52.7 ± 4.6 | 28/15 | NA | SCC, ADC | advanced | chemo-therapy | 3 months | 125.08 ± 14.89 | 43 | 89.77 ± 11.35 | 43 |
53.4 ± 3.6 | 26/18 | NA | SCC, ADC | advanced | chemo-therapy + TCM | 3 months | 126.56 ± 14.57 | 44 | 78.12 ± 8.12 | 44 |